

Nutrición Hospitalaria



Trabajo Original

Nutrición artificial

Home enteral nutrition: clinical-nutritional analysis and outcomes of 10 years of public policy

Nutrición enteral domiciliaria: análisis clínico-nutricional de los 10 años de política pública

Caryna Eurich Mazur¹, Renata Carolyne Chavoni Zago², Maria Eliana Madalozzo Schieferdecker² and Eliane Mara Cesário Pereira Maluf¹

Postgraduate Programs in ¹Internal Medicine and ²Food and Nutrition. Federal University of Paraná. Curitiba, Paraná. Brazil

Abstract

Background and aims: home enteral nutrition (HEN) is an established treatment for clinically stable patients. The objective of this study was to determine the frequency and the situation of patients in HEN, in the capital city in the south of Brazil.

Methods: in this retrospective study, we recorded all new cases of HEN in adults in Curitiba, Brazil, from January 2006 to December 2015. Data were collected by a dietitian from medical records of patients attending public health settings. The following data were analyzed: clinical diagnosis, diet prescribed during hospitalization and at discharge, and feeding access types. Kaplan-Meier and Cox regression analyses were used to calculate survival.

Results: a total of 1,231 patients were included. There was a 425% increase in the frequency of HEN over the years studied. The mean age was 66.7 years, and 54.4% were men. Neurological diseases were the most prevalent (46.4%), followed by cancer (33.6%). Eight hundred and one patients (65.1%) died during this period. Mean HEN duration was 180 days (95% Cl 163.6-193.4), with a significant difference between neurological diseases (median: 180 days) and cancer (median: 210 days) (p < 0.05). Neurological disease was an independent risk factor for mortality in patients on HEN (HR: 1.17; Cl: 1.08-1.27).

Conclusions: the study shows an increase in HEN. Neurological diseases prevailed and presented a risk of mortality, and more than half of the patients with NED died in this period.

Key words:

Enteral feeding. Enteral nutrition. Adults. Elderly.

Resumen

Introducción y objetivos: la nutrición enteral domiciliaria (NED) es un tratamiento establecido para pacientes clínicamente estables. El objetivo de este estudio fue determinar la frecuencia y la situación de los pacientes con NED en la capital del sur de Brasil.

Métodos: en este estudio retrospectivo se registraron todos los nuevos casos de NED en adultos en Curitiba, Brasil, de enero de 2006 a diciembre de 2015. Los datos fueron recolectados por un nutricionista de historiales clínicos de pacientes que frecuentan establecimientos de salud pública. Se analizaron los siguientes datos: diagnóstico clínico, dieta prescrita durante la estancia hospitalaria y en el momento del alta y acceso alimenticio. Se utilizaron los análisis de Kaplan-Meier y regresión de Cox para calcular la supervivencia.

Resultados: fueron incluidos 1.231 pacientes. Hubo un aumento del 425% en la frecuencia de NED a lo largo de los años estudiados. La edad media fue de 66,7 años y el 54,4% eran hombres. Las enfermedades neurológicas fueron las más prevalentes (46,4%), seguidas de las neoplasias (33,6%). Durante este periodo murieron 801 pacientes (65,1%). La duración media de la NED fue de 180 días (IC 95%, 163,6-193,4), con una diferencia significativa entre enfermedades neurológicas (mediana: 180 días) y cáncer (mediana: 210 días) (p < 0,05). La enfermedad neurológica fue un factor de riesgo independiente para la mortalidad en pacientes en NED (HR: 1,17; IC: 1,08-1,27).

Conclusiones: el estudio muestra un aumento en la NED. Las enfermedades neurológicas prevalecieron y presentaron riesgo de mortalidad y más de la mitad de los pacientes murieron durante la NED.

Palabras clave:

Alimentación enteral. Nutrición enteral. Adultos. Persona mayor.

Received: 04/04/2019 • Accepted: 14/05/2019

Mazur CE, Zago RCC, Schieferdecker MEM, Maluf EMCP. Home enteral nutrition: clinical-nutritional analysis and outcomes of 10 years of public policy. Nutr Hosp 2019;36(4):758-763 DOI: http://dx.doi.org/10.20960/nh.02606

Correspondence:

Caryna Eurich Mazur. Postgraduate Program in Internal Medicine. Federal University of Paraná. General Carneiro, 181. Alto da Gloria. Curitiba, Brazil e-mail: carynanutricionista@gmail.com

INTRODUCTION

Home enteral nutrition (HEN) is a therapy for stable patients who need long-term care without the need of hospitalization (1). HEN is a model of care of growing importance, aimed at optimizing diet transition, improving patient's quality of life and reducing treatment-related costs compared with hospital care (2).

The use of HEN has increased worldwide. In Italy, the incidence (per million population per year) and the prevalence (per million population) of patients receiving HEN was 223.4 and 279.4, respectively, between 2001 and 2005 (3). In Spain, from 1999 to 2010 the incidence of patients receiving HEN was three per million inhabitants (4). In Poland, the number of patients with HEN increased from 5.4 to 46.6 per million inhabitants in five years (2008-2013) (5). However, in Brazil, there are no data available on the characteristics of individuals treated with HEN provided by the Unified Health System, but this is not an impediment to conducting cross-sectional surveys and without intervention on the topic. A prevalence study conducted in Federal District, Brazil, in Zaban and Novaes (6) showed a prevalence of 175.64 cases per million inhabitants and an incidence of 147.98 cases per million inhabitants per year in 2005.

In Curitiba, Brazil, the Nutrition Assistance Program for People with Special Dietary Needs (PAN) began in 2006 with the objective of providing nutritional assistance and tools for nutritional care of HEN patients. The program is a milestone for the Brazilian Unified Health System and has been recognized internationally as a model for HEN care.

The knowledge of epidemiological data of patients receiving HEN is necessary for the development of effective and cost-effective public policies. Thus, the objective of this study was to determine the frequency and the situation of patients on HEN, in the capital city in the south of Brazil.

MATERIALS AND METHODS

We retrospectively analyzed the data of adult patients on HEN between January 2006 and December 2015, beneficiary of the PAN. The study was approved by the Ethics Committee of the Curitiba Secretary of Health and by the Ethics Committee of the Federal University of Paraná (49265615.1.0000.0102/2015).

Data were collected from the medical records in public health centers of the city. For the purposes of analysis, data were collected in the first and last home visits of all patients, adults and elderly, registered in the PAN. The outcomes were categorized as discharge, continuation in PAN or death.

Baseline diagnosis and associated diseases, previous HEN as well as HEN access were evaluated.

STATISTICAL ANALYSIS

The survival curves were evaluated using the Kaplan-Meier method, defined as the time interval between PAN inclusion and death. The follow-up time was defined as the median time intervals, and the variable of interest was death from any cause. "Survivors" were defined as those patients who were either withdrawn or discharged from the PAN. Life table analysis and Kaplan-Meier curves were performed to assess the duration of the HEN. The Cox proportional hazards analysis was used to assess which variables were correlated with survival. Statistical data were generated with the IBM SPSS Statistics 22.0 (Chicago, IL, USA). All statistical tests were two sided, and p < 0.05 was used to indicate statistical significance.

RESULTS

The study included 1,231 individuals on HEN. Curitiba's population was estimated to be 1,893,997 in 2015, distributed in a territorial area of 435,036 km² (population density of 4,027 inhabitants/km²). Most of the population are adults (87.3%) and women, and the most prevalent age group is 30-34 years old.

Figure 1 depicts the frequency of patients on HEN, including total number, the number of survivors and the number of deaths from 2006 to 2015. There was an exponential increase (425%) in HEN in the years studied, with a peak in 2013. The number of deaths was considerably higher compared to survivors from 2006 to 2013, although these rates were similar in 2015.

Mean age was 66.7 ± 17.6 years; 68.0% (n = 837) were elderly. The majority of the sample was male (n = 670; 54.4%). Nasogastric tube was the main route of administration (38.3%). Diet prescription by dietitians at the hospital was mostly tube feeding formula (50.6%), whereas at home, patients were mostly prescribed a blended diet (38.6%) (Table I).

The most prevalent diagnoses were neurological diseases (46.4%), especially stroke (28.8%) and Alzheimer disease (9.2); cancer (33.6%), especially head and neck (14.3%) and esophagus (8.9%); and trauma (7.1%) (Table II). Among comorbidities, there was a high prevalence of systemic arterial hypertension (586, 47.8%) and diabetes mellitus (243, 19.8%).

Neurological diseases were the most prevalent in every year of the study period, except in the year 2015, where cancer was the most prevalent. The other diseases showed a similar frequency throughout the years, except for kidney diseases that increased in the year 2015 (Fig. 2).

Of the 1,231 patients on HEN, 65.1% (n = 801) died, 21.0% achieved full oral nutrition, 5.9% continued on HEN, 5.3% moved to another city and in 2.9% the outcome was not reported. Figure 3 shows the Kaplan-Meier survival curves for all patients. Overall, the median survival was 180 days (95% Cl: 163.6-193.4). A significant difference (p > 0.05) was found between the survival of patients with neurological diseases (median survival of 180 days), cancer (median survival of 210 days) and other diseases (median survival of 150 days).

Cox proportional hazards model was employed, assuming duration of HEN as exposure time and 801 deaths as failure endpoint. This analysis showed that neurological disease was an independent risk factor for mortality in patients on HEN. However, gender, nasogastric tube, commercial formulas during hospitalization, blended diet at home, gravity feeding, oral supplementation and presence of a caregiver were not risk factors for mortality in HEN patients (Table III).

760 C. E. Mazur et al.




Figure 1.Frequency of patients (total number, number of survivors and number of deaths) on home enteral nutrition in a ten-year period in Curitiba, Brazil.

Table I. Characteristics of the home enteral nutrition prescribed to patients (n = 1,231) in Curitiba, Brazil, from 2006 to 2015

	Frequency (%)
Types of tube [*]	
Nasograstric tube	472 (38.3)
Jejunal tube	204 (16.6)
Gastrostomy tube	421 (34.2)
Jejunostomy tube	131 (10.6)
Types of enteral diet at hospital discharge [†]	
Blended diet	228 (21.4)
Tube feeding formula	538 (50.6)
Combination of above	298 (28.0)
Types of tube feeding at home‡	
Blended diet	456 (38.6)
Tube feeding formula	335 (28.4)
Combination of above	389 (33.0)
Tube feeding schedule at home§	
Gravity	1,107 (90.3)
Bolus feeding	59 (4.8)
Oral	57 (4.6)
Infusion pump	3 (0.2)
Oral supplementation ^I	382 (31.3)
Caregiver ¹	1,161 (95.1)

^{*}Missing data n = 3. †Missing data n = 167. †Missing data n = 51. §Missing data n = 5. †Missing data n = 12. ¶Number of patients whose home enteral nutrition was performed by a caregiver; missing data n = 10.

DISCUSSION

This study shows the frequency of patients on HEN in Curitiba, Brazil, from 2006 to 2015. The number of HEN patients considerably increased during this period; however, it was not possible to establish the prevalence of HEN patients, especially due to

Table II. Prevalence of diseases (International Classification of Diseases, 10th revision, ICD-10) in patients (n = 1,231) on home enteral nutrition in Curitiba, Brazil, from 2006 to 2015

Neurological diseases 571 (46.4) Stroke 354 (28.8) Alzheimer's disease 113 (9.1) Parkinson 31 (2.5) Cerebral palsy 18 (1.5) Amyotrophic lateral sclerosis 16 (1.3) Others 39 (3.2) Cancer 414 (33.6) Head and neck 176 (14.3) Esophagus 110 (8.9) Stomach and intestine 61 (5.0) Central nervous system 15 (1.2) Others 52 (4.2) Trauma 88 (7.1) Trauma injury 39 (3.2) Polytrauma 18 (1.4) Others 31 (2.5) Diseases of the digestive system 33 (2.7) Hepatic cirrhosis 6 (0.5) Cron's disease 4 (0.3) Others 23 (1.9) Renal diseases 29 (2.4) Chronic kidney disease 27 (2.2) Acute kidney disease 24 (1.9) Type 2 diabetes mellitus 9 (0.7) Metabolic diseases 24 (1.9)	ICD-10 version: 2016 classification	n (%)		
Alzheimer's disease 113 (9.1) Parkinson 31 (2.5) Cerebral palsy 18 (1.5) Amyotrophic lateral sclerosis 16 (1.3) Others 39 (3.2) Cancer 414 (33.6) Head and neck 176 (14.3) Esophagus 110 (8.9) Stomach and intestine 61 (5.0) Central nervous system 15 (1.2) Others 52 (4.2) Trauma 88 (7.1) Trauma in injury 39 (3.2) Polytrauma 18 (1.4) Others 31 (2.5) Diseases of the digestive system 33 (2.7) Hepatic cirrhosis 6 (0.5) Crohn's disease 4 (0.3) Others 23 (1.9) Renal diseases 29 (2.4) Chronic kidney disease 29 (2.4) Chronic kidney diseases 24 (1.9) Type 2 diabetes mellitus 9 (0.7) Malnutrition 10 (0.8) Others 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others	Neurological diseases	571 (46.4)		
Parkinson 31 (2.5) Cerebral palsy 18 (1.5) Amyotrophic lateral sclerosis 16 (1.3) Others 39 (3.2) Cancer 414 (33.6) Head and neck 176 (14.3) Esophagus 110 (8.9) Stomach and intestine 61 (5.0) Central nervous system 15 (1.2) Others 52 (4.2) Trauma 88 (7.1) Traumaic brain injury 39 (3.2) Polytrauma 18 (1.4) Others 31 (2.5) Diseases of the digestive system 33 (2.7) Hepatic cirrhosis 6 (0.5) Crohn's disease 4 (0.3) Others 23 (1.9) Renal diseases 29 (2.4) Chronic kidney disease 29 (2.4) Chronic kidney disease 24 (1.9) Type 2 diabetes mellitus 9 (0.7) Malnutrition 10 (0.8) Others 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7)	Stroke	354 (28.8)		
Cerebral palsy 18 (1.5) Amyotrophic lateral sclerosis 16 (1.3) Others 39 (3.2) Cancer 414 (33.6) Head and neck 176 (14.3) Esophagus 110 (8.9) Stomach and intestine 61 (5.0) Central nervous system 15 (1.2) Others 52 (4.2) Trauma 88 (7.1) Trauma 88 (7.1) Trauma 18 (1.4) Others 31 (2.5) Diseases of the digestive system 33 (2.7) Hepatic cirrhosis 6 (0.5) Crohn's disease 4 (0.3) Others 23 (1.9) Renal diseases 29 (2.4) Chronic kidney disease 27 (2.2) Acute kidney disease 22 (0.2) Metabolic diseases 24 (1.9) Type 2 diabetes mellitus 9 (0.7) Malnutrition 10 (0.8) Others 5 (0.4) Pulmonary disease 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9)	Alzheimer's disease	113 (9.1)		
Amyotrophic lateral sclerosis 16 (1.3) Others 39 (3.2) Cancer 414 (33.6) Head and neck 176 (14.3) Esophagus 110 (8.9) Stomach and intestine 61 (5.0) Central nervous system 15 (1.2) Others 52 (4.2) Trauma 88 (7.1) Traumatic brain injury 39 (3.2) Polytrauma 18 (1.4) Others 31 (2.5) Diseases of the digestive system 33 (2.7) Hepatic cirrhosis 6 (0.5) Crohn's disease 4 (0.3) Others 23 (1.9) Renal diseases 29 (2.4) Chronic kidney disease 29 (2.4) Chronic kidney disease 20 (0.2) Metabolic diseases 24 (1.9) Type 2 diabetes mellitus 9 (0.7) Malnutrition 10 (0.8) Others 5 (0.4) Pulmonary diseases 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 9 (0.7) Cardiciov	Parkinson	31 (2.5)		
Others 39 (3.2) Cancer 414 (33.6) Head and neck 176 (14.3) Esophagus 110 (8.9) Stomach and intestine 61 (5.0) Central nervous system 15 (1.2) Others 52 (4.2) Trauma 88 (7.1) Traumaic brain injury 39 (3.2) Polytrauma 18 (1.4) Others 31 (2.5) Diseases of the digestive system 33 (2.7) Hepatic cirrhosis 6 (0.5) Crohn's disease 4 (0.3) Others 23 (1.9) Renal diseases 29 (2.4) Chronic kidney disease 29 (2.4) Chronic kidney disease 29 (2.4) Chronic kidney disease 24 (1.9) Type 2 diabetes mellitus 9 (0.7) Malnutrition 10 (0.8) Others 5 (0.4) Pulmonary diseases 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 20 (1.6) <	Cerebral palsy	18 (1.5)		
Cancer 414 (33.6) Head and neck 176 (14.3) Esophagus 110 (8.9) Stomach and intestine 61 (5.0) Central nervous system 15 (1.2) Others 52 (4.2) Trauma 88 (7.1) Traumatic brain injury 39 (3.2) Polytrauma 18 (1.4) Others 31 (2.5) Diseases of the digestive system 33 (2.7) Hepatic cirrhosis 6 (0.5) Crohn's disease 4 (0.3) Others 23 (1.9) Renal diseases 29 (2.4) Chronic kidney disease 27 (2.2) Acute kidney diseases 24 (1.9) Type 2 diabetes mellitus 9 (0.7) Malnutrition 10 (0.8) Others 5 (0.4) Pulmonary diseases 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular d	Amyotrophic lateral sclerosis	16 (1.3)		
Head and neck 176 (14.3) Esophagus 110 (8.9) Stomach and intestine 61 (5.0) Central nervous system 15 (1.2) Others 52 (4.2) Trauma 88 (7.1) Traumatic brain injury 39 (3.2) Polytrauma 18 (1.4) Others 31 (2.5) Diseases of the digestive system 33 (2.7) Hepatic cirrhosis 6 (0.5) Crohn's disease 4 (0.3) Others 23 (1.9) Renal diseases 29 (2.4) Chronic kidney disease 27 (2.2) Acute kidney disease 2 (0.2) Metabolic diseases 24 (1.9) Type 2 diabetes mellitus 9 (0.7) Malnutrition 10 (0.8) Others 5 (0.4) Pulmonary diseases 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardiac insufficiency<	Others			
Esophagus 110 (8.9) Stomach and intestine 61 (5.0) Central nervous system 15 (1.2) Others 52 (4.2) Trauma 88 (7.1) Traumatic brain injury 39 (3.2) Polytrauma 18 (1.4) Others 31 (2.5) Diseases of the digestive system 33 (2.7) Hepatic cirrhosis 6 (0.5) Crohn's disease 4 (0.3) Others 23 (1.9) Renal diseases 29 (2.4) Chronic kidney disease 27 (2.2) Acute kidney diseases 2 (0.2) Metabolic diseases 24 (1.9) Type 2 diabetes mellitus 9 (0.7) Malnutrition 10 (0.8) Others 5 (0.4) Pulmonary diseases 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) <td< td=""><td>Cancer</td><td>414 (33.6)</td></td<>	Cancer	414 (33.6)		
Stomach and intestine 61 (5.0) Central nervous system 15 (1.2) Others 52 (4.2) Trauma 88 (7.1) Traumatic brain injury 39 (3.2) Polytrauma 18 (1.4) Others 31 (2.5) Diseases of the digestive system 33 (2.7) Hepatic cirrhosis 6 (0.5) Crohn's disease 4 (0.3) Others 23 (1.9) Renal diseases 29 (2.4) Chronic kidney disease 27 (2.2) Acute kidney diseases 24 (1.9) Type 2 diabetes mellitus 9 (0.7) Malnutrition 10 (0.8) Others 5 (0.4) Pulmonary diseases 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardiac insufficiency 13 (1.1) Others 6 (0.4)	Head and neck	176 (14.3)		
Central nervous system 15 (1.2) Others 52 (4.2) Trauma 88 (7.1) Traumatic brain injury 39 (3.2) Polytrauma 18 (1.4) Others 31 (2.5) Diseases of the digestive system 33 (2.7) Hepatic cirrhosis 6 (0.5) Crohn's disease 4 (0.3) Others 23 (1.9) Renal diseases 29 (2.4) Chronic kidney disease 27 (2.2) Acute kidney diseases 24 (1.9) Type 2 diabetes mellitus 9 (0.7) Malnutrition 10 (0.8) Others 5 (0.4) Pulmonary diseases 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardiac insufficiency 13 (1.1) Others 6 (0.4)	Esophagus	110 (8.9)		
Others 52 (4.2) Trauma 88 (7.1) Traumatic brain injury 39 (3.2) Polytrauma 18 (1.4) Others 31 (2.5) Diseases of the digestive system 33 (2.7) Hepatic cirrhosis 6 (0.5) Crohn's disease 4 (0.3) Others 23 (1.9) Renal diseases 29 (2.4) Chronic kidney disease 27 (2.2) Acute kidney diseases 2 (0.2) Metabolic diseases 24 (1.9) Type 2 diabetes mellitus 9 (0.7) Malnutrition 10 (0.8) Others 5 (0.4) Pulmonary diseases 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardiac insufficiency 13 (1.1) Others 6 (0.4)	Stomach and intestine	61 (5.0)		
Trauma 88 (7.1) Traumatic brain injury 39 (3.2) Polytrauma 18 (1.4) Others 31 (2.5) Diseases of the digestive system 33 (2.7) Hepatic cirrhosis 6 (0.5) Crohn's disease 4 (0.3) Others 23 (1.9) Renal diseases 29 (2.4) Chronic kidney disease 27 (2.2) Acute kidney diseases 24 (1.9) Type 2 diabetes mellitus 9 (0.7) Malnutrition 10 (0.8) Others 5 (0.4) Pulmonary diseases 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardioi insufficiency 13 (1.1) Others 6 (0.4)	Central nervous system	15 (1.2)		
Trauma 88 (7.1) Traumatic brain injury 39 (3.2) Polytrauma 18 (1.4) Others 31 (2.5) Diseases of the digestive system 33 (2.7) Hepatic cirrhosis 6 (0.5) Crohn's disease 4 (0.3) Others 23 (1.9) Renal diseases 29 (2.4) Chronic kidney disease 27 (2.2) Acute kidney diseases 24 (1.9) Type 2 diabetes mellitus 9 (0.7) Malnutrition 10 (0.8) Others 5 (0.4) Pulmonary diseases 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardioi insufficiency 13 (1.1) Others 6 (0.4)	Others	52 (4.2)		
Polytrauma 18 (1.4) Others 31 (2.5) Diseases of the digestive system 33 (2.7) Hepatic cirrhosis 6 (0.5) Crohn's disease 4 (0.3) Others 23 (1.9) Renal diseases 29 (2.4) Chronic kidney disease 27 (2.2) Acute kidney disease 2 (0.2) Metabolic diseases 24 (1.9) Type 2 diabetes mellitus 9 (0.7) Malnutrition 10 (0.8) Others 5 (0.4) Pulmonary diseases 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardiac insufficiency 13 (1.1) Others 6 (0.4)	Trauma			
Polytrauma 18 (1.4) Others 31 (2.5) Diseases of the digestive system 33 (2.7) Hepatic cirrhosis 6 (0.5) Crohn's disease 4 (0.3) Others 23 (1.9) Renal diseases 29 (2.4) Chronic kidney disease 27 (2.2) Acute kidney disease 2 (0.2) Metabolic diseases 24 (1.9) Type 2 diabetes mellitus 9 (0.7) Malnutrition 10 (0.8) Others 5 (0.4) Pulmonary diseases 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardiac insufficiency 13 (1.1) Others 6 (0.4)	Traumatic brain injury	39 (3.2)		
Others 31 (2.5) Diseases of the digestive system 33 (2.7) Hepatic cirrhosis 6 (0.5) Crohn's disease 4 (0.3) Others 23 (1.9) Renal diseases 29 (2.4) Chronic kidney disease 27 (2.2) Acute kidney disease 2 (0.2) Metabolic diseases 24 (1.9) Type 2 diabetes mellitus 9 (0.7) Malnutrition 10 (0.8) Others 5 (0.4) Pulmonary diseases 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardiac insufficiency 13 (1.1) Others 6 (0.4)				
Diseases of the digestive system 33 (2.7) Hepatic cirrhosis 6 (0.5) Crohn's disease 4 (0.3) Others 23 (1.9) Renal diseases 29 (2.4) Chronic kidney disease 27 (2.2) Acute kidney disease 2 (0.2) Metabolic diseases 24 (1.9) Type 2 diabetes mellitus 9 (0.7) Malnutrition 10 (0.8) Others 5 (0.4) Pulmonary diseases 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 4 (0.3) Infections 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardiac insufficiency 13 (1.1) Others 6 (0.4)	_ ·			
Hepatic cirrhosis 6 (0.5) Crohn's disease 4 (0.3) Others 23 (1.9) Renal diseases 29 (2.4) Chronic kidney disease 27 (2.2) Acute kidney disease 2 (0.2) Metabolic diseases 24 (1.9) Type 2 diabetes mellitus 9 (0.7) Malnutrition 10 (0.8) Others 5 (0.4) Pulmonary diseases 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 4 (0.3) Infections 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardioac insufficiency 13 (1.1) Others 6 (0.4)	Diseases of the digestive system			
Crohn's disease 4 (0.3) Others 23 (1.9) Renal diseases 29 (2.4) Chronic kidney disease 27 (2.2) Acute kidney disease 2 (0.2) Metabolic diseases 24 (1.9) Type 2 diabetes mellitus 9 (0.7) Malnutrition 10 (0.8) Others 5 (0.4) Pulmonary diseases 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardiac insufficiency 13 (1.1) Others 6 (0.4)		` ′		
Renal diseases 29 (2.4) Chronic kidney disease 27 (2.2) Acute kidney disease 2 (0.2) Metabolic diseases 24 (1.9) Type 2 diabetes mellitus 9 (0.7) Malnutrition 10 (0.8) Others 5 (0.4) Pulmonary diseases 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 4 (0.3) Infections 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardiac insufficiency 13 (1.1) Others 6 (0.4)	l '			
Chronic kidney disease 27 (2.2) Acute kidney disease 2 (0.2) Metabolic diseases 24 (1.9) Type 2 diabetes mellitus 9 (0.7) Malnutrition 10 (0.8) Others 5 (0.4) Pulmonary diseases 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 4 (0.3) Infections 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardiac insufficiency 13 (1.1) Others 6 (0.4)	Others	23 (1.9)		
Acute kidney disease 2 (0.2) Metabolic diseases 24 (1.9) Type 2 diabetes mellitus 9 (0.7) Malnutrition 10 (0.8) Others 5 (0.4) Pulmonary diseases 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 4 (0.3) Infections 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardiac insufficiency 13 (1.1) Others 6 (0.4)	Renal diseases	29 (2.4)		
Metabolic diseases 24 (1.9) Type 2 diabetes mellitus 9 (0.7) Malnutrition 10 (0.8) Others 5 (0.4) Pulmonary diseases 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 4 (0.3) Infections 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardiac insufficiency 13 (1.1) Others 6 (0.4)	Chronic kidney disease	27 (2.2)		
Type 2 diabetes mellitus 9 (0.7) Malnutrition 10 (0.8) Others 5 (0.4) Pulmonary diseases 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 4 (0.3) Infections 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardiac insufficiency 13 (1.1) Others 6 (0.4)	Acute kidney disease	2 (0.2)		
Malnutrition 10 (0.8) Others 5 (0.4) Pulmonary diseases 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 4 (0.3) Infections 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardiac insufficiency 13 (1.1) Others 6 (0.4)	Metabolic diseases	24 (1.9)		
Others 5 (0.4) Pulmonary diseases 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 4 (0.3) Infections 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardiac insufficiency 13 (1.1) Others 6 (0.4)	Type 2 diabetes mellitus	` '		
Others 5 (0.4) Pulmonary diseases 23 (1.9) Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 4 (0.3) Infections 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardiac insufficiency 13 (1.1) Others 6 (0.4)	Malnutrition	10 (0.8)		
Chronic obstructive pulmonary disease 11 (0.9) Pneumonia 8 (0.7) Others 4 (0.3) Infections 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardiac insufficiency 13 (1.1) Others 6 (0.4)	Others	5 (0.4)		
Pneumonia 8 (0.7) Others 4 (0.3) Infections 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardiac insufficiency 13 (1.1) Others 6 (0.4)	Pulmonary diseases	23 (1.9)		
Others 4 (0.3) Infections 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardiac insufficiency 13 (1.1) Others 6 (0.4)	Chronic obstructive pulmonary disease	11 (0.9)		
Infections 20 (1.6) AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardiac insufficiency 13 (1.1) Others 6 (0.4)	Pneumonia	8 (0.7)		
AIDS 11 (0.9) Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardiac insufficiency 13 (1.1) Others 6 (0.4)	Others	4 (0.3)		
Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardiac insufficiency 13 (1.1) Others 6 (0.4)	Infections	20 (1.6)		
Others 9 (0.7) Cardiovascular diseases 19 (1.5) Cardiac insufficiency 13 (1.1) Others 6 (0.4)	AIDS	` '		
Cardiovascular diseases19 (1.5)Cardiac insufficiency13 (1.1)Others6 (0.4)	Others			
Cardiac insufficiency 13 (1.1) Others 6 (0.4)	Cardiovascular diseases			
Others 6 (0.4)				
	· ·			
UHITH HISTASES TU (U.O)	Other diseases	10 (0.8)		

underregistration of cases, particularly of those with less severe conditions, and also because health records were not in electronic format, contributing to missing data.

In some countries, such as Poland, Great Britain, Spain and Italy, epidemiological data of HEN patients are annually recorded.




Figure 2.Descriptive time series of the most prevalent diagnoses of patients (n = 1,231) on home enteral nutrition in Curitiba, Brazil, between 2006 and 2015.




Figure 3.Kaplan-Meier overall survival curve in patients on home enteral nutrition (n = 1,231) in Curitiba, Brazil, between 2006 and 2015.

However, data on HEN from Latin American populations are scarce in the literature. In Brazil, Zaban and Novaes (6) reported an increase in both incidence and prevalence of HEN patients over a five-year period in the Federal District.

Santarpia et al. (1) reported an increase from 355 patients on HEN in 2005 to 1,165 in 2012. Nevertheless, unlike our study, the authors considered not only patients on HEN, but also on parenteral and oral nutrition. Mundi et al. (9), in a prevalence study conducted in 2013 in the United States, showed a prevalence of 437.88 HEN patients per million population; in adults, this number was 248.85. The number of patients on HEN increased considerably from 1992 to 2013 (231.4%). In Spain, De Luis et al. (4) reported that the prevalence of HEN patients increased from 9.52 in 1999 to 30.0 in 2010 per 100,000 inhabitants. In Poland, the prevalence of HEN increased from 5.4 to 47.6/1,000,000 inhabitants from 2008 to 2013 (5).

Table III. Cox regression model with hazard ratio (HR) and 95% confidence intervals (95% CI) for mortality in patients on home enteral nutrition

	Adjusted HR	95% CI	р
Neurological diseases	1.17	1.08-1.27	0.00
Male gender	0.99	0.91-1.08	0.85
Nasograstric tube	1.08	0.99-1.17	0.08
Commercial formula (at the hospital)	0.96	0.89-1.05	0.38
Blended diet (at home)	0.97	0.90-1.06	0.57
Gravity feeding (at home)	1.08	0.95-1.23	0.25
Oral supplementation	0.94	0.86-1.03	0.17
Caregiver	1.08	0.88-1.34	0.42

In our study, most of the patients were men (54.4%), similarly to other studies (4,5), but different to others (3,11,12).

In this study, the mean age of the sample was 66.7 years, like the study by De Luis et al. (4) (68.5 years), the study by Klek et al. (5) (61.4 years) and others (11,12). In our study, the elderly accounted for 68.0% of the sample. Wong et al. (2), in a systematic review, showed that most patients of HEN-related studies were elderly.

Although most patients were on long-term enteral nutrition support, the nasograstric tube was the main route of administration (38.3%). In seven years of follow-up, Morelo et al. (3) also demonstrated that nasograstric tube was the most predominant feeding route. A long period on nasogastric feeding can cause an exponential increase in the risk for complications (e.g., infection and mechanical complications) in the access site. On the other hand, European studies (5,11) have shown that gastrostomy tube

762 C. E. Mazur et al.

and jejunostomy tube were more commonly used for long term enteral nutrition therapy (5,11). However, although both gastrostomy and jejunostomy are safe ways to provide food to patients, placement of these long-term access tubes requires surgery and is expensive in Brazil.

In our study, it was shown that most dietitians prescribe commercial diets at hospital discharge of patients with HEN (50.6%). It is known that the use of commercial products in HEN reduces the frequency of hospitalization for infections and pneumonia of home patients (2). That would also reduce costs with HEN. Nevertheless, there is a low subsidy for these products, and the Brazilian Unified Health System provides limited funding and use strict criteria for dispensing these products. In this regard, patients with severe malnutrition, patients with cancer as primary diagnosis, and those with degenerative diseases are considered as a priority by the Unified Health System and the PAN. If, on the one hand, commercial formulas are the "diet of choice" for enteral nutrition support, on the other hand, a blenderized diet was prescribed to 38.6% of patients on HEN. Ginzburg et al. (12) warn that little attention has been paid to the lack of communication between the hospital setting and the community. Since most HEN patients have chronic diseases, homemade diet can be a cheaper alternative for the patients, their families and the health system as well (14). It is worth mentioning, however, that although homeblend feedings are a very convenient solution, the risk of tube clogging and underfeeding due to low protein/energy value of the diets should be considered. In the present study, there was no association of homemade diet with survival.

Neurological diseases, especially stroke (28.8%), were the most prevalent in our sample (46.4%). Dysphagia is usually the indication for HEN in these diseases. Similar prevalence of neurological diseases has been reported by other authors (3-5,10,13). Santarpia et al. (1) showed that neurological diseases increased 327% in adults and 287% in the elderly in a seven-year follow-up study. In a recent study, Orlandoni et al. (13) demonstrated that patients with dementia had better chances of survival than patients without dementia, with no statistical significance though.

We found a high prevalence of cancer (33.6%), mainly head and neck cancer (14.3%). The prevalence of cancer patients on HEN varies in the literature, ranging from 2.7%, as reported by Morelo et al. (3), to 34.1%, found by De Kuis et al. (4). In the study by Santarpia et al. (1), the incidence of cancer increased by 327% in adults and 359% in the elderly during the seven years of follow-up.

In our study, neurological patients had lower survival rates than cancer patients, maybe because of their poorer health status. Although this was a follow-up study, conclusions about the association of survival with nutritional status, complications or adherence to HEN cannot be drawn due to the lack of data. Ginzburg et al. (12), in Israel, reported a decrease in adherence to HEN and an increase in HEN complications and mortality over time.

Mean duration of HEN was 180 days in our study. In the study by Morelo et al. (3), the median duration of HEN was 296-307 days among neurological diseases patients, 258 days in stroke patients, 71 days in head and neck cancer patients and 97 days

among patients with abdominal cancer. In a study by De Luis et al. (4) mean time on HEN was 159.9 days; 75 patients died and 691 survived. Age was significantly related to survival (HR 1.03; 95% Cl 1.01-1.05, p < 0.05) and 49.4% progressed to oral nutrition by the end of the study.

Because this is one of the first studies in Brazil, especially in the southern region of the country, it would be interesting to perform a nationwide multicenter study. HEN is a rapidly expanding modality of health care, and public policies for such therapy should be implemented and routinely evaluated based on time series analysis. A nationwide multicentric study would also allow to describe the current situation of the Brazilian Unified System in terms of coverage and support for patients on HEN.

HEN aims to improve the quality of life of the patient, in addition to enabling recovery of health. In light of the high hospital system costs, HEN may be not only a cost-effective alternative, but also a way of individualizing and humanizing health care. Besides, HEN requires a closer integration of the multidisciplinary team, especially the dietitian, with the patient and the family. Re-evaluation and improvement of public policies for HEN in developing countries such as Brazil is needed.

In conclusion, our findings show a high frequency of patients on HEN, with a predominance of men, patients with neurological diseases and cancer. Survival rates varied according to the diagnosis, with an association of neurological diseases with poor survival.

AUTHOR CONTRIBUTIONS

Caryna Eurich Mazur was responsible for the design, data analysis, interpretation and writing of the article. The other authors contributed to the writing and final revision of the article.

ACKNOWLEDGMENTS

We thank the CAPES (Coordination for the Improvement of Higher Level Personnel) by granting the scholarship. We thank the Curitiba Secretariat of Health, especially Patricia Audrey Reis Gonçalves and Angela Cristina Lucas, for their valuable contributions to this study.

REFERENCES

- Santarpia L, Pagano MC, Pasanisi F, Contaldo F. Home artificial nutrition: an update seven years after the regional regulation. Clin Nutr 2014;33(5):872-8.
- Wong A, Goh G, Bancks MD, Bauer JD. A systematic review of the cost and economic outcomes of enteral nutrition. Clin Nutr 2017;37(2):429-42.
- Morello M, Marcon ML, Laviano A, Giometto M, Baruffi C, Zulian E, et al. Enteral nutrition in nursing home residents: a 5-year (2001-2005) epidemiological analysis. Nutr Clin Pract 2009;24(5):635-41.
- De Luis DA, Izaola O, Cuellar LA, Terroba MC, Cabezas G, De La Fuente B. Experience over 12 years with home enteral nutrition in a healthcare area of Spain. J Hum Nutr Diet 2013;26(Suppl 1):39-44.
- Klek S, Pawlowska D, Dziwiszek G, Komón H, Compala P, Nawojski M. The evolution of home enteral nutrition (HEN) in Poland during five years after implementation: a multicentre study. Nutr Hosp 2015;32(1):196-201.

- Zaban ALRS, Novaes MRCG. Impact of the home enteral nutrition regulation issue in public hospitals in Distrito Federal, Brazil. Euro J Clin Nutr Metab 2009;4(4):193-8.
- Hebuterne X, Bozzetti F, Moreno Villares JM, Pertkiewicz M, Shaffer J, Staun M, et al; ESPEN-Home Artificial Nutrition Working Group. Home enteral nutrition in adults: a European multicentre survey. Clin Nutr 2003;22(3):261-6.
- 8. Santarpia L, Pagano MC, Pasanisi F, Contaldo F. Home artificial nutrition: an update seven years after the regional regulation. Clin Nutr 2014;33:872-8.
- Mundi MS, Pattinson A, McMahon MT, Davidson J, Hurt RT. Prevalence of home parenteral and enteral nutrition in the United States. Nutr Clin Pract 2017;32(6):799-805.
- Klek S, Hermanowicz A, Dziwiszek G, Matysiak K, Szczepanek K, Szybinski P, et al. Home enteral nutrition reduces complications, length of stay and health care costs: results from a multicenter study. Am J Clin Nutr 2014;100(2):609-15.
- Taibo RV, Olmos MÁM, Guerrero DB, Casariego AV, García RP, Sueiro AM, et al. Epidemiology of home enteral nutrition: an approximation to reality. Nutr Hosp 2018;35(3):511-8.
- Ginzburg Y, Shmilovitz I, Monastyrsky N, Endevelt R, Shahar DR. Barriers for nutritional care in the transition from hospital to the Community among older patients. Clin Nutr ESPEN 2018;25:56-62.
- Orlandoni P, Peladic NJ, Di Rosa M, Venturini C, Fagnani D, Sparvoli D, et al. The outcomes of long term home enteral nutrition (HEN) in older patients with severe dementia. Clin Nutr 2019;38(4):1871-6. pii: S0261-5614(18)31212-3.
- Vieira MMC, Santos VFN, Bottini A, Morais TB. Nutritional and microbiological quality of comercial and homemade blenderized whole food enteral diets for home-based enteral nutritional therapy in adults. Clin Nutr 2018;37:177-81.